Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glialia microgranuli
- Development stage
- Unknown
- Lead developer
- Epitech
- Modality
- Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Glialia microgranuli is a food for special medical purposes (medical food/nutraceutical) developed by Epitech Group SpA. It is a fixed-dose combination of palmitoylethanolamide (PEA, 700 mg) and luteolin (70 mg) in a co-ultramicronized form known as the ultramicrocomposite PEALUT®. Glialia microgranuli is administered orally via the sublingual route and is indicated for the dietary management of neuroinflammatory processes associated with central nervous system disorders. These include transient ischemic attacks (TIA), post-ischemic stroke states, post-traumatic CNS conditions, mild cognitive decline, early-stage dementia, early-stage Parkinsonism, inflammatory demyelinating diseases, motor neuron diseases, and mood disorders. The active ingredients act synergistically to modulate non-neuronal cells involved in neuroinflammation, specifically microglia, astrocytes, and mast cells, thereby exerting neuroprotective effects.
- Brand names
- GlialiaGlialia microgranuli
- Other names
- co-ultramicronized palmitoylethanolamide and luteolinpalmitoylethanolamide + luteolinPEALUTultramicrocomposite PEALUT
02
Targets
CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)PDE4 (Phosphodiesterase 4A1)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Glialia microgranuli.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glialia microgranuli.